Global Extended Release Drug Market Growth (Status and Outlook) 2023-2029

Global Extended Release Drug Market Growth (Status and Outlook) 2023-2029

Drug delivery systems are engineered technologies for controlled release of drugs or to the targeted delivery of drugs. Drug delivery system is a kind of formulation that enables the administration of therapeutic agents in the body and improves its safety and efficacy by controlling the time, rate and place of drug release in the body. Most of the conventional oral products of drugs are formulated to release the active ingredient as soon as it is administered. Now the pattern has been changed to modified release dosage forms to achieve better therapeutic target. Extended release drugs is a type of dosage forms which allows a two-fold reduction in frequency of dosage administered in the body.

LPI (LP Information)' newest research report, the “Extended Release Drug Industry Forecast” looks at past sales and reviews total world Extended Release Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Extended Release Drug sales for 2023 through 2029. With Extended Release Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Extended Release Drug industry.

This Insight Report provides a comprehensive analysis of the global Extended Release Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Extended Release Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Extended Release Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Extended Release Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Extended Release Drug.

The global Extended Release Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Extended Release Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Extended Release Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Extended Release Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Extended Release Drug players cover Pfizer, Mallinckrodt, Teva, Johnson & Johnson, Endo Pharmaceuticals, Purdue Pharma, Mylan, Hisamitsu Pharmaceutical and Sun Pharmaceutical Industries, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Extended Release Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Sustained Release Drug
Controlled Release Drug

Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Mallinckrodt
Teva
Johnson & Johnson
Endo Pharmaceuticals
Purdue Pharma
Mylan
Hisamitsu Pharmaceutical
Sun Pharmaceutical Industries

Please note: The report will take approximately 2 business days to prepare and deliver.